These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 9693223)

  • 21. Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats.
    Laleman W; Van Landeghem L; Van der Elst I; Zeegers M; Fevery J; Nevens F
    Gastroenterology; 2007 Feb; 132(2):709-19. PubMed ID: 17258737
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transplantation of endothelial progenitor cells ameliorates vascular dysfunction and portal hypertension in carbon tetrachloride-induced rat liver cirrhotic model.
    Sakamoto M; Nakamura T; Torimura T; Iwamoto H; Masuda H; Koga H; Abe M; Hashimoto O; Ueno T; Sata M
    J Gastroenterol Hepatol; 2013 Jan; 28(1):168-78. PubMed ID: 22849788
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alterations in mechanical properties of mesenteric resistance arteries in experimental portal hypertension.
    Resch M; Wiest R; Moleda L; Fredersdorf S; Stoelcker B; Schroeder JA; Schölmerich J; Endemann DH
    Am J Physiol Gastrointest Liver Physiol; 2009 Oct; 297(4):G849-57. PubMed ID: 19696142
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Celecoxib and octreotide synergistically ameliorate portal hypertension via inhibition of angiogenesis in cirrhotic rats.
    Gao JH; Wen SL; Feng S; Yang WJ; Lu YY; Tong H; Liu R; Tang SH; Huang ZY; Tang YM; Yang JH; Xie HQ; Tang CW
    Angiogenesis; 2016 Oct; 19(4):501-11. PubMed ID: 27380212
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular mechanisms of increased intrahepatic resistance in portal hypertension.
    Shah V
    J Clin Gastroenterol; 2007; 41 Suppl 3():S259-61. PubMed ID: 17975474
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased blood flow through the portal system in cirrhotic rats.
    Vorobioff J; Bredfeldt JE; Groszmann RJ
    Gastroenterology; 1984 Nov; 87(5):1120-6. PubMed ID: 6479534
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatic venous pressure gradient in 2010: optimal measurement is key.
    Burroughs AK; Thalheimer U
    Hepatology; 2010 Jun; 51(6):1894-6. PubMed ID: 20512984
    [No Abstract]   [Full Text] [Related]  

  • 28. Biology of hepatic stellate cells and their possible relevance in the pathogenesis of portal hypertension in cirrhosis.
    Pinzani M; Gentilini P
    Semin Liver Dis; 1999; 19(4):397-410. PubMed ID: 10643625
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanism of portal hypertensive gastropathy: an unresolved issue.
    Lo GH
    J Gastroenterol Hepatol; 2009 Sep; 24(9):1482-3. PubMed ID: 19743994
    [No Abstract]   [Full Text] [Related]  

  • 30. Regulation of sinusoidal perfusion in portal hypertension.
    Reynaert H; Urbain D; Geerts A
    Anat Rec (Hoboken); 2008 Jun; 291(6):693-8. PubMed ID: 18484616
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Preoperative evaluation of hemodynamics and the functional state of the liver in cirrhosis].
    Anisimova SM
    Vestn Khir Im I I Grek; 1972 Dec; 109(12):32-5. PubMed ID: 4664077
    [No Abstract]   [Full Text] [Related]  

  • 32. High-frequency vagus nerve stimulation improves portal hypertension in cirrhotic rats.
    Bockx I; Verdrengh K; Vander Elst I; van Pelt J; Nevens F; Laleman W; Cassiman D
    Gut; 2012 Apr; 61(4):604-12. PubMed ID: 22187073
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Amiloride reduces portal hypertension in rat liver cirrhosis.
    Steib CJ; Hennenberg M; Beitinger F; Hartmann AC; Bystron M; De Toni EN; Gerbes AL
    Gut; 2010 Jun; 59(6):827-36. PubMed ID: 20551467
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduced contractility and histological changes in the gallbladder due to portal hypertension in a hamster cirrhosis model.
    Sakata R; Ueno T; Torimura T; Sata M; Tanikawa K
    Digestion; 1997; 58(5):444-51. PubMed ID: 9383635
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Experimental reduction of portal hypertension by mechanical increase of liver portal flow.
    Habib N; Houssin D; Carol C; Cardoso J; Boisseau C; Calmus Y; Ozier Y; Quere J; Wood C; McIntyre N
    Lancet; 1991 Jan; 337(8732):16-7. PubMed ID: 1670651
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Noninvasive assessment of portal hypertension in cirrhosis: liver stiffness and beyond.
    Stefanescu H; Procopet B
    World J Gastroenterol; 2014 Dec; 20(45):16811-9. PubMed ID: 25492995
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The cardiac abnormalities in liver cirrhotic patients with portal hypertension].
    Li L; Ping CX; Zhang B; Dong PL; Yan HY; Ding HG
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jun; 17(6):462-3. PubMed ID: 19567029
    [No Abstract]   [Full Text] [Related]  

  • 38. Role of endothelial nitric oxide synthase in the development of portal hypertension in the carbon tetrachloride-induced liver fibrosis model.
    Theodorakis NG; Wang YN; Wu JM; Maluccio MA; Sitzmann JV; Skill NJ
    Am J Physiol Gastrointest Liver Physiol; 2009 Oct; 297(4):G792-9. PubMed ID: 19628654
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Portal hypertensive gastropathy].
    Tao XH
    Zhonghua Gan Zang Bing Za Zhi; 2009 Apr; 17(4):254-6. PubMed ID: 19403020
    [No Abstract]   [Full Text] [Related]  

  • 40. Endogenously produced cannabinoids and liver cirrhosis.
    Senior K
    Lancet; 2001 Jul; 358(9275):42. PubMed ID: 11454385
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.